"For patients, navigating the debate can be difficult because doctors, patient advocacy groups and manufacturers often endorse positions that are in their economic self-interest." The New York Times
Corporate business ethics and investors’ interests have swept aside the humanitarian foundation of American medicine and most of related healthcare, and caring service professions.
In the first half of the twenty-first century, U.S. psychiatrists are prescribing the second generation neuroleptics—Zyprexa, Risperdal, Geodon, Seroquel, Abilfy—to coerce innocent children and the elderly into submission.
It is difficult to comprehend, why the Obama administration, which has made cost-cutting a legislative centerpiece of healthcare reform, would remove the most potent, financial penalty in its existing legal arsenal from its settlement with Pfizer.
Pfizer, the world’s largest drug manufacturer has the dubious distinction of being a corporate "repeat offender…"
"The story’s pretty clear, and pretty embarrassing for the profession of psychiatry, which has allowed itself to be led by marketing," says Dr. Robert Rosenheck, Yale.
The Hill , a newspaper covering congressional news, reports: "Sen. Chuck Grassley (Iowa) is considering leaving his powerful post as senior Republican on the Finance Committee so that he can become the highest-ranking Republican on the Judiciary panel. To avoid a dramatic shake-up, Grassley is hoping to strike a deal…
The most shocking disclosure is that Dr. Biederman’s study testing powerful antipsychotics in PRESCHOOL CHILDREN "was beset by breaches of research protocol,"
The most shocking disclosure: a Biederman study testing the use of powerful antipsychotics in PRESCHOOL CHILDREN "was beset by breaches of research protocol."
New revelations in an unsealed whistleblower-initiated lawsuit filed in Boston add yet another dimension to the scope and magnitude of corruption that has derailed American medicine–the focus is tainted Continuing Medical Education.
The Washington Post suggests, the chance for success in overhauling US healthcare depends on President Obama's ability to keep the major–discordant–players on board.
